---
title: "Philip Morris International 2026: Revenue $11.19B, EPS $1.8— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293744546.md"
description: "Philip Morris International reported Q2 2026 results with revenue rising 10.4% to $11.19B, driven by pricing and smoke-free product growth. However, net earnings fell 7.3% to $2.82B, and diluted EPS declined 7.7% to $1.8. Smoke-free volumes increased 8.3%, while combustible cigarette sales dropped 1.9%. The company highlighted expanded availability of IQOS, ZYN, and VEEV, along with key FDA authorizations and U.S. commercialization advances."
datetime: "2026-07-24T10:51:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293744546.md)
  - [en](https://longbridge.com/en/news/293744546.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293744546.md)
generator: "portal-rs"
---

# Philip Morris International 2026: Revenue $11.19B, EPS $1.8— 10-Q Summary

Philip Morris International reported results for the quarter ended 2026 with revenue rising to $11.19B while net earnings attributable to PMI decreased to $2.82B and diluted EPS fell to $1.8 versus the prior-year quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$11.19B

$10.14B

10.4%

Net income²

$2.82B

$3.04B

(7.3%)

Diluted EPS³

$1.8

$1.95

(7.7%)

*¹ Reported as “Net revenues 1 & 2 (Note 13)”. ² Reported as “Net earnings attributable to PMI”. ³ Reported as “Diluted earnings per share”.*

**Business Highlights**

-   Net revenues rose 9.8% year-to-date to $21.3B, driven by pricing and growth in smoke-free products despite declines in combustible volumes.
-   Smoke-free volumes grew 8.3% YTD (HTUs +9.4%, e-vapor +72%), while cigarettes declined 1.9%, indicating continued portfolio transition.
-   Brand momentum continued with expanded availability of IQOS, ZYN and VEEV across markets; IQOS and ZYN received major FDA marketing and MRTP authorizations.
-   U.S. commercialization advances included regaining full IQOS U.S. rights, an IQOS 3.0 pilot launch, and progress on ILUMA regulatory submissions.
-   Company actions included lower restructuring charges, footprint optimization, and capex focused on smoke-free manufacturing expansion.

Original SEC Filing: Philip Morris International Inc. \[ PM \] - 10-Q - Jul. 24, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PM.US](https://longbridge.com/en/quote/PM.US.md)
- [XPM.US](https://longbridge.com/en/quote/XPM.US.md)

## Related News & Research

- [PM: Smoke-free growth accelerates in Japan and the U.S., with strong focus on IQOS and ZYN innovation](https://longbridge.com/en/news/298342595.md)
- [PM: 2026 EPS guidance raised on robust smoke-free growth and expanded product offerings](https://longbridge.com/en/news/298333250.md)
- [Did PMI’s New Altria Manufacturing Deal Just Recast Philip Morris International's (PM) Investment Narrative?](https://longbridge.com/en/news/297828464.md)
- [Philip Morris lifts 2026 reported diluted EPS view to USD 7.28-7.43 on currency impact](https://longbridge.com/en/news/298311472.md)
- [HighTower Advisors LLC Purchases 9,240 Shares of Philip Morris International Inc. $PM](https://longbridge.com/en/news/298200198.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**